In a patient vaccinated against hepatitis B eight years ago who now has a positive hepatitis B surface antigen (HBsAg) and negative hepatitis B surface antibody (anti‑HBs), what does this indicate and how should it be managed?

Positive HBsAg with Negative Anti-HBs After Vaccination: Chronic Hepatitis B Infection

This patient has chronic hepatitis B infection, not vaccine failure. The presence of HBsAg indicates active HBV infection, and the hepatitis B vaccine does not produce HBsAg—only natural infection does 1, 2.

Understanding the Serologic Pattern

Key principle: Hepatitis B vaccination induces only anti-HBs antibodies (surface antibody), never HBsAg (surface antigen) 2. The vaccine contains purified surface antigen protein that stimulates antibody production but cannot cause infection or produce circulating HBsAg 1.

• HBsAg positivity for more than 6 months defines chronic hepatitis B infection 1
• Negative anti-HBs in this context indicates the patient either lost vaccine-induced immunity before infection occurred, or never mounted an adequate response to vaccination 1, 2
• The 8-year interval since vaccination is sufficient time for antibody levels to wane below protective thresholds in some individuals, though immunologic memory typically persists 1, 2

Essential Diagnostic Workup

Complete the following serologic and virologic panel immediately to characterize the infection phase and guide management 1:

• Anti-HBc (total and IgM) – Confirms natural infection (will be positive; vaccine never induces anti-HBc) 1, 2
• HBeAg and anti-HBe – Determines immune phase and replication status 1
• HBV DNA quantitative – Essential for assessing viral replication and treatment indication 1
• ALT/AST – Evaluates hepatic inflammation 1
• Complete blood count, INR, albumin, bilirubin – Assesses liver synthetic function 1
• Hepatitis A antibodies (anti-HAV) – If negative, vaccinate (coinfection increases mortality 5.6- to 29-fold) 1
• HIV, hepatitis C, hepatitis D testing – Rule out coinfections that alter prognosis 1

Management Algorithm Based on Test Results

If HBV DNA >2000 IU/mL and ALT Elevated (>ULN):

Consider treatment when HBV DNA >2000 IU/mL, ALT above upper limit of normal, and moderate-to-severe necroinflammation or at least moderate fibrosis on biopsy or non-invasive assessment 1. Treatment may be initiated even with normal ALT if HBV DNA and histologic criteria are met 1.

• First-line agents: Entecavir 0.5 mg daily or tenofovir 245 mg daily (nucleos(t)ide analogues with high barrier to resistance) 1
• Alternative: Pegylated interferon-α (if patient prefers finite therapy and has no contraindications) 1
• Non-invasive fibrosis assessment (FibroScan/elastography) is useful to stratify disease severity 1

If HBV DNA <2000 IU/mL and ALT Persistently Normal:

This patient may be an inactive HBV carrier 1. Management requires:

• Minimum 1-year observation with ALT every 3–4 months and HBV DNA measurement to confirm inactive carrier state 1
• Lifelong monitoring with ALT every 6 months after the first year and periodic HBV DNA levels 1
• Closer surveillance if HBV DNA 2000–20,000 IU/mL; consider non-invasive fibrosis evaluation or liver biopsy 1
• Inactive carriers have very low risk of cirrhosis or HCC but can reactivate to active disease 1

If HBeAg-Positive with High HBV DNA (>20,000 IU/mL):

• Age <30 years with persistently normal ALT and no family history of HCC/cirrhosis: Follow every 3–6 months without immediate biopsy or therapy 1
• Age ≥30 years or family history of HCC/cirrhosis: Consider liver biopsy and treatment even with normal ALT 1

If HBeAg-Negative with Fluctuating ALT and HBV DNA:

This represents HBeAg-negative chronic hepatitis B, which has low rates of spontaneous remission and high risk of progression 1. Requires careful assessment over at least 1 year with ALT every 3–4 months and periodic HBV DNA to distinguish from inactive carrier state 1.

Critical Pitfalls to Avoid

• Do not assume vaccine failure or need for revaccination—HBsAg positivity indicates infection, not inadequate vaccine response 1, 2
• Do not delay anti-HBc testing—this single test confirms natural infection versus the impossible scenario of vaccine-induced HBsAg 1, 2
• Do not overlook rare vaccine escape mutants (e.g., G145R mutation), though these account for <1% of breakthrough infections and do not alter initial management 3
• Concurrent anti-HBs and HBsAg positivity occurs in approximately 10% of chronic infections due to low-level anti-HBs that is non-protective; this does not indicate immunity 4
• Do not assume protection from isolated anti-HBs in the absence of anti-HBc—this pattern (if not vaccine-induced) may represent cross-reactive antibodies or response to mutant strains and is not protective 5

Counseling and Prevention

• Household and sexual contacts should be tested (HBsAg, anti-HBc, anti-HBs) and vaccinated if susceptible 1
• Barrier protection (condoms) until contacts complete vaccination series and achieve anti-HBs ≥10 mIU/mL 1
• Abstinence from alcohol (increases progression to cirrhosis and HCC) 1
• Smoking cessation (associated with worse outcomes) 1
• Hepatitis A vaccination if anti-HAV negative 1
• HCC surveillance with ultrasound ± alpha-fetoprotein every 6 months once diagnosis and phase are established 1